January 24, 2003

Gilead Sciences to Release Fourth Quarter and Year-End 2002 Financial Results on Thursday, January 30, 2003; Conference Call and Webcast to Follow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 24, 2003--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its fourth quarter and Year End 2002 financial results will be released on Thursday, January 30, 2002, at 4:00 p.m. Eastern Time. At 4:30 p.m. Gilead will webcast a conference call live on the company's internet site. The call will be led by John Martin, PhD, President and Chief Executive Officer, Mark Perry, Executive Vice President of Operations, and John Milligan, PhD, Senior Vice President and Chief Financial Officer.

To access the live call or the seven-day archive via the internet, log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to view the webcast. Alternatively, please call 1-800-967-7134 (U.S.) or 1-719-457-2625 (international) to access the call. Telephone replay is available approximately two hours after the call through 8:30 p.m. EST, February 2, 2002. To access, please call 888-203-1112 (U.S.) or 719-457-0820 (international). The conference ID number is 182919.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has six marketed products and focuses its research and clinical programs on anti-infectives, including antivirals, antifungals and antibacterials. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.

For more information on Gilead Sciences, please visit the company's web site at www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

--30--DC/sf*

CONTACT:Gilead Sciences, Inc.
Susan Hubbard, 650/522-5715
(Investor Relations)

Other News

Some of the content on this page is not intended for users outside the U.S.